Company Filing History:
Years Active: 2021
Title: The Innovative Work of Mingyang Chang in Cellular Reprogramming
Introduction
Mingyang Chang, a prominent inventor based in Beijing, China, has made significant contributions to the field of cellular reprogramming. With a patent registered under his name, he has explored innovative techniques to convert digestive tract-derived epithelial cells into endodermal stem and progenitor cells, showcasing a promising frontier in regenerative medicine.
Latest Patents
Mingyang Chang holds a valuable patent titled "Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application." This groundbreaking invention provides a compound combination that utilizes human gastric epithelial cells as initiating cells and human gastric subepithelial myofibroblasts as a trophoblast. The patent outlines the use of a specific combination of compounds including FBP, Bay K 8644, Bix01294, SB431542, A813-01, VPA, RG108, PD0325901, and PS48 to facilitate the reprogramming process. The resulting endodermal stem/progenitor cells can then be differentiated to develop into liver cells, pancreatic beta cells, and intestinal cells.
Career Highlights
Chang is affiliated with the Institute of Transfusion Medicine, Academy of Military Medical Sciences, People's Liberation Army of China. His work emphasizes a strong focus on the intersection of molecular biology and therapeutic applications, particularly in regenerative medicine. His patent reflects his dedication to advancing medical science and improving therapeutic techniques.
Collaborations
Throughout his career, Mingyang Chang has collaborated with several esteemed colleagues, including Yunfang Wang and Shuyong Wang. Their combined expertise aids in pushing the boundaries of current research and potentially enhancing the outcomes of cellular reprogramming and differentiation.
Conclusion
Mingyang Chang's innovative approach in cellular reprogramming marks a significant achievement in biomedical research. His ongoing contributions, supported by collaborators and a robust institutional framework, pave the way for future advancements in regenerative therapies and hold promise for treating a variety of medical conditions.